Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilisation and robotic egg freezing, announced the launch of its ICSI. A Centre of Excellence Program, with the first clinical deployments of the world's first automated intracytoplasmic sperm injection (ICSI) workstation at five leading fertility centres: CERAS in Peru, Memorial Hospital in Turkey, CENALFES in Bolivia, Seoul IVF in South Korea, and Procrearte in Argentina. Together, these centres become among the first clinics in the world to bring automated ICSI into live clinical use, establishing a reference model for how fertility networks can deliver consistent, reproducible outcomes at the most technically demanding step of IVF.
ICSI is the most complex and consequential manual procedure performed in any IVF laboratory. Carried out entirely by hand under a microscope, its outcomes have always depended on the individual embryologist's dexterity, training, and physical condition on a given day, as well as on cycle-to-cycle variation within even the most skilled operators. As global IVF demand rises with later family formation and the broader adoption of fertility care, reliance on manual technique for the single most critical step has become a structural constraint on both quality and scale.
ICSI.A addresses this directly. The platform introduces robotics and computer vision into the injection step itself, standardising parameters across every case regardless of operator and materially reducing the risk of human error at the most delicate point in the process. Critically, the platform augments rather than replaces the embryologist. By removing the physical burden and variability of manual injection, ICSI.A frees clinical teams to focus on higher-order judgment, patient care, and laboratory strategy, elevating the role of the embryologist in the modern IVF lab while allowing clinics to scale throughput without compromising quality.
"This is a turning point for reproductive medicine. For the first time, the most decisive step in IVF is no longer left to chance, and that changes what every clinic in the world can promise its patients," said Hans Gangeskar, CEO of Overture Life. "CERAS, Memorial Hospital, CENALFES, Seoul IVF, and Procrearte are not waiting for the field to catch up. They are building the fully automated, fully reproducible IVF laboratory now, and in doing so, they are setting the standard the rest of the industry will be measured against."
Each centre brings distinct regional leadership to the program. CERAS, a flagship fertility centre in Peru, anchors the program in Latin America and positions the country at the frontier of reproductive automation. Memorial Hospital, one of Turkey's leading fertility centres and a trusted destination for patients from neighbouring countries and across the globe, has established itself as a regional reference site for the international community, particularly in the field of reproductive genetics. CENALFES brings a particularly fitting heritage to the program: the centre was the first clinic in Latin America to incorporate micromanipulators in 1994, presenting its first cases the following year. More than three decades later, it again steps to the front of the field by becoming one of the first centres in the world to perform automated ICSI. Seoul IVF has built its reputation on prioritising safety and precision through careful evaluation of clinical data. At the same time, the clinic has actively pursued automation solutions designed to minimise human error and improve consistency throughout the IVF process.
“This has always come down to a single question: who gets to have a family. The most advanced fertility care has never been evenly distributed, and closing that gap is why I built CERAS. CERAS has been a pioneer in incorporating advanced technologies in reproductive medicine, including AI-assisted embryo assessment, electronic witnessing systems, time-lapse incubation, and now automated ICSI. ICSI. A lets us deliver the most demanding step in IVF with a consistency that no longer rests on a handful of expert hands, which means we can extend that quality to far more patients than before. Bringing this technology to Peru reflects our commitment to ensuring that world-class reproductive care is available to patients throughout Latin America. Innovation only fulfils its purpose when it helps more people access safe, effective, and consistent fertility treatment,” said Dr Fabrizio Vizcarra, Founder and Medical Director of CERAS.
"As a centre that introduced the first ICSI, embryo freezing and PGT applications in Turkey, we have a long-standing commitment to medical innovation. With ICSI.A, we ensure a consistent level of quality in the most critical step of treatment: the microinjection. However, our focus remains equally on the rigor of our laboratory quality control systems. Patients choose our centre because they know we maintain these high standards consistently across every treatment. For us, success is the result of combining scientific innovation with a disciplined, patient-centred approach," said Prof. Dr Semra Kahraman, Director of Istanbul Memorial Hospital.
